ArticleCancer medicine2025
Survival Prediction in Middle-Aged and Elderly Patients With Burkitt Lymphoma: A Comprehensive Nomogram Approach Based on SEER Data.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBurkitt lymphoma (BL) in middle-aged and elderly populations presents unique prognostic challenges due to distinct biological behaviors and therapeutic vulnerabilities. Current prognostic tools inadequately address age-specific survival determinants in this understudied cohort.
methodsThis study used the Surveillance, Epidemiology, and End Results (SEER) data from patients diagnosed with BL between 2000 and 2020, aged 45 years and older. Through univariate and multivariate Cox regression analyses, we identified independent prognostic factors affecting overall survival (OS) and cancer-specific survival (CSS). Finally, nomograms were constructed, and the models were evaluated across three dimensions.
resultsMultivariate analysis results indicated that factors such as age, race, Ann Arbor stage, and chemotherapy were independently associated with OS, while age, Ann Arbor stage, radiotherapy, chemotherapy, and number of tumor masses were independently associated with CSS. The nomogram model effectively predicted the 1-, 3-, and 5-year probabilities of OS and CSS. The results from receiver operating characteristic curves, calibration curves, and decision curve analysis in the training and validation groups confirmed that the risk prediction nomogram could accurately predict the survival of BL patients.
conclusionThe nomogram model constructed in this study provides a personalized survival prediction tool for BL patients, effectively distinguishing the survival probabilities of different risk groups. This research offers new insights for risk stratification and treatment management of middle-aged and elderly BL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.